Difficulties and countermeasures for the international acceptance of clinical trial data in ChinaSUN Yi-bu, HAO Zi-ruo, CHEN Yu-wenChinese Journal of New Drugs2025, No.23002026-08Pharmacoeconomic evaluation of jiuwei zhike oral liquid in the treatment of acute bronchitis with cough due to windheat syndromeCHEN Yu, FANG Gang, PI Zhi-peng et al.Chinese Journal of New Drugs2025, No.22002026-08Analysis and reflection on the marketing authorization of innovative traditional Chinese medicine drugs since 2020WU Chen-yue, HAN Wei, QU Jian-bo et al.Chinese Journal of New Drugs2025, No.22002026-08Inhibitory effect and mechanism of IgD-Fc-Ig fusion protein on human rheumatoid cell modelLING Xi, XU Jing, LI Chao-yuan et al.Chinese Journal of New Drugs2025, No.22002026-08Advances in anti-Chikungunya fever drugsLI Jin-yu, LI Song, ZHONG WuChinese Journal of New Drugs2025, No.22002026-08Research progress and clinical application prospect of betel nut and its active components:pharmacological and toxicological effectsYUAN Shao-shuang, SUN Zheng-qing, ZHANG Zhao-hui et al.Chinese Journal of New Drugs2025, No.22002026-08From FDA Complete Response Letters on the pharmaceutical assessment of chemical drugs:critical deficiencies and review considerationsREN Feng, CHENG Si-qi, JIANG Tao et al.Chinese Journal of New Drugs2025, No.23002026-08Common issues and review considerations for the packaging systems of therapeutic recombinant biological productsWU Yong-kai, LI Qian, WEI Wei et al.Chinese Journal of New Drugs2025, No.24002026-08Recent advances in the development and regulatory pharmaceutical evaluation of dual-payload antibody-drug conjugatesCHEN Hao, LI Qian, WEI WeiChinese Journal of New Drugs2025, No.24002026-08Considerations for elemental impurity control strategies of recombinant protein products based on ICH Q3D(R2)KOU Ya-zhen, WEI Wei, HE WuChinese Journal of New Drugs2025, No.24002026-08Application of platform technology and regulatory considerations for innovative monoclonal antibody productsQIU Xiao, WANG Wen-bo, YANG Fei et al.Chinese Journal of New Drugs2025, No.24002026-08Clinical characteristics of four cases of myositis,myocarditis and myasthenia gravis overlap syndrome induced by immune checkpoint inhibitorsLI Xiao, ZHANG Yan-huaChinese Journal of New Drugs2025, No.23002026-08Construction and exploration of information management system for biological samples in phase Ⅰ clinical trialsSHEN Jie, LI Sha, ZHAO Juan et al.Chinese Journal of New Drugs2025, No.23002026-08Clinical comprehensive evaluation of drugs for acute ischemic strokeWANG Yu-fei, JI Xin-yue, TIAN LeiChinese Journal of New Drugs2026, No.02002026-08Study on risk-sharing agreements in South Korea and its implication for medical insurance admission in ChinaZHANG Tian-qi, ZENG Liu-chun, ZHANG Wen et al.Chinese Journal of New Drugs2026, No.02002026-08General considerations for the development and similarity evaluation of dulaglutide biosimilarsHU Ying-ying, CHENG Su-yuanChinese Journal of New Drugs2025, No.24002026-08Considerations on establishing quality standards of specific human immunoglobulin productsJIA Yan-hua, JIA Dong-chen, YU Peng-li et al.Chinese Journal of New Drugs2025, No.24002026-08Pharmaceutical technical requirements and prospects for cell-based regenerative medicine therapeutic drugsHAN Dong-mei, DONG Jing, WEI WeiChinese Journal of New Drugs2025, No.24002026-08Requirements for re-registration of biological products in ChinaYUAN Rong-rongChinese Journal of New Drugs2025, No.24002026-08Analysis of the current status and trends in recombinant protein vaccine research and developmentXU Li, LI Huan, LIU Min et al.Chinese Journal of New Drugs2025, No.24002026-08 